Research Article Details
| Article ID: | A10247 |
| PMID: | 31413241 |
| Source: | J Oleo Sci |
| Title: | Elaeagnus mollis Oil Attenuates Non-alcoholic Fatty Disease in High-fat Diet Induced Obese Mice via Modifying the Expression of Lipid Metabolismrelated Genes. |
| Abstract: | Elaeagnus mollis oil (EMO), which is a type of plant oil, was extracted from the nuts of Elaeagnus mollis Diels that is known as a precious woodyoilcrop in China. The present study investigated the ameliorative effects of EMO on high-fat diet-induced non-alcoholic fatty liver disease (NAFLD) and explored relative regulation mechanism. The analysis of EMO fatty acids showed that EMO rich in unsaturated fatty acids (92.07%), such as linoleic acid (48.24%), oleic acid (34.20%) and linolenic acid (7.57%). In addition, supplementation of EMO could ameliorate the increase in body weight, fat weight, and abnormal serum lipids induced by high-fat diet. A further important implication is that the levels of serum ALT, serum AST, hepatic TG, TC, SOD, GSH/GSSG ration and MDA were improved after supplementing with EMO. All these changes may be due to the ability of EMO to inhibit fatty acid synthesis via reducing the mRNA expression of SREBP-1c, PPARγ and FAS, and elevate fatty acid oxidation by increasing the mRNA expression of PPARα and CPT-1. Meanwhile, our results also showed that endogenously synthesized n-3 PUFAs could significantly increase after treating with EMO. In conclusion, the results suggested that EMO could be regarded as a healthy food for preventing NAFLD. |
| DOI: | 10.5650/jos.ess19078 |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs | |
|---|---|---|---|---|---|
| S02 | Enhance lipid metabolism | triglyceride-lowering; lipid tolerance; lipid metabolism | 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) inhibitor; Decreases intestinal cholesterol absorption; FXR agonist; ACC inhibitor; FAS inhibitor; DGAT2 inhibitor; SCD-1 inhibitor | Atorvastatin; Ezetimibe; Obeticholic Acid; GS-9674; GS-0976; TVB-2640; IONIS-DGAT2rx; Aramchol; | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I14 | 9970 | Obesity | An overnutrition that is characterized by excess body fat, traditionally defined as an elevated ratio of weight to height (specifically 30 kilograms per meter squared), has_material_basis_in a multifactorial etiology related to excess nutrition intake, decreased caloric utilization, and genetic susceptibility, and possibly medications and certain disorders of metabolism, endocrine function, and mental illness. https://en.wikipedia.org/wiki/Obesity | disease of metabolism/acquired metabolic disease/ nutrition disease/overnutrition | Details |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D328 | Serine | Chemical drug | DB00133 | SRR | Improve insulin resistance | Under clinical trials | Details |
| D504 | Polyunsaturated Fatty Acids | Supplement | -- | -- | -- | Under clinical trials | Details |
| D094 | Cysteamine | Chemical drug | DB00847 | GSS stimulant | Renal drug | Under clinical trials | Details |
| D158 | Glutathione | Chemical drug | DB00143 | MGST3; HPGDS; GSTM2; GSTM5; GPX7 cofactor; MGST2; GSS; GSTM1; GSTK1; GSTM3; GSTM4; GPX1 cofactor; GPX2 cofactor; GPX3 cofactor | -- | Under clinical trials | Details |
| D095 | Cysteamine bitartrate | Chemical drug | DB00847 | -- | -- | Under clinical trials | Details |